


## **GENERATING NEW KNOWLEDGE**



It's been a very productive year for our funded researchers with a total of 155 new publications reported to us in the last submission period.



The 90 journal publications were most frequently published in:

- Neuro-Oncology
- Neuropathology and Applied Neurobiology
- Paediatric Blood & Cancer
- 4. Child's Nervous System: ChNS: official journal of the International Society for Paediatric Neurosurgery
- 5. Journal of Neuro-Oncology, Neuro-Oncology Advances and Neuro-Oncology Practice

The 63 abstracts were presented at the following conferences most frequently:

- 1. International Symposium on Paediatric Neuro-Oncology (ISPNO)
- 2. Society for Neuro-Oncology (SNO)
- 3. British Neuropathological Society (BNS)

### ALSO REPORTED

book

contributions

6 new research tools or methods including a patient-derived cell repository which is being disseminated worldwide.

11 new databases or data handling systems which have the potential to make, or are already making, a significant difference to research.



Since the launch of our first research strategy 'A Cure Can't Wait' in 2015, our funded research has resulted in 386 publications, contributing a wealth of knowledge to the field, and helping to shape the directions of future research.

### **RESEARCH IN THE MEDIA SPOTLIGHT -**REDEFINING MENINGIOMA CLASSIFICATION



By combining the stories from researchers with the experiences from our wider community we show the impact of our research on people every day.

This PR piece in October 2021 covered both the story of nurse and mother-of-two Tammy Andrews, who had been diagnosed with a meningioma, and a publication on DNA methylation profiling in meningioma resulting from a grant part-funded by The Brain Tumour Charity and led by Dr Gelareh Zadeh in Toronto. This story, featured in multiple news outlets, had an estimated audience reach of 1.6m and was also used across our social media channels.

"This truly is a significant research milestone which will enable meningioma brain tumours to be analysed and classified, and hopefully in future targeted with an effective medical therapy that could save lives." **Tammy Andrews** 

Paper: doi:10.1093/neuonc/noz061

PR piece: https://www.dorsetecho.co.uk/news/19648959.dorset-nurse-supports-possible-meningioma-tumour-treatment

## INFLUENCING POLICY AND OTHER **STAKEHOLDERS**

Significant influence on policy, practice, patients and the public was reported including:

TO GUIDELINE COMMITTEES SUCH AS WHO

12 MEMBERSHIPS

CLINICAL GUIDELINES

2 CITATIONS IN

NHS ENGLAND FOR THE NATIONWIDE ADOPTION OF 5-ALA

A RECOMMENDATION BY

#### SPOTLIGHT ON INFLUENCE Several of our funded researchers contributed to the World Health Organisation's new international guidance on the classification of brain tumours, widely used in neuro-oncology and beyond.

research to explore new, but related, research.

80

70


# £9.5M OF FURTHER FUNDING

STIMULATING NEW RESEARCH

Further funding of £9.5m was obtained in the year 2020-2021 as a result of our funded

This means that, since 2015, our funded research has attracted over £48m in further funding.

**FURTHER FUNDING BREAKDOWN BY SECTOR (%)** 



## AWARDS AND RECOGNITION

We were informed of several awards or other significant forms of recognition received in the last year, including:



RESEARCH PRIZES





**IMPACT** Increased visibility of research through local and international press coverage, board memberships and new collaborations were among the types of impact reported to us as a result of these awards and other forms of recognition.

## ALSO REPORTED

62 engagement activities such as speaking at international conferences, hosting lab tours and

speaking at fundraising events. A phase II clinical trial is in the initial development stages.

2 new international collaborations.

© The Brain Tumour Charity 2022. Registered Charity no. 1150054 (England and Wales) SC045081 (Scotland)